May 15 |
Cabaletta Bio GAAP EPS of -$0.51
|
May 15 |
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 13 |
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
May 5 |
Wall Street Breakfast: The Week Ahead
|
Mar 23 |
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
|
Mar 21 |
Cabaletta Bio files automatic mixed securities shelf
|
Mar 21 |
Cabaletta Bio GAAP EPS of -$0.46
|
Mar 21 |
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 20 |
Cabaletta gets FDA orphan drug status for systemic sclerosis drug
|
Mar 20 |
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
|